ASCO 2017: Identifying and Targeting Genetic Drivers in Rare Genitourinary Cancer Types

Chicago, IL ( Dr. Sonpavde gave a summary of 3 posters: 4516 – Dr. Eric Jonasch, 4517 – Dr. Sumanta K. Pal, and 4518 – Dr. Simon Rodney. The first poster (4516) was a Phase II study of pazopanib in patients with von Hippel-Lindau disease. Dr. Sonpavde gave a brief background on VHL disease. This disease is a mutation of the the VHL tumor suppressor gene. It is a rare autosomal dominant disease with a prevalence of 1:35000-40000.

ASCO GU 2017: Best of Journals: Renal Cell Carcinoma – Medical Oncology - Session Highlights

Orlando, Florida USA ( In this session, Dr. Brugarolas reviewed the past year’s literature on renal cell carcinoma (RCC) from the medical oncology perspective. He highlighted two adjuvant studies (S-TRAC and ASSURE), Checkmate 025, METEOR, and a first-in-class HIF2α inhibitor trial.

ASCO GU 2017: Optimal Selection of Front-Line Therapies for Metastatic Renal Cell Carcinoma - Session Highlights

Orlando, Florida USA ( Dr. Ulka N. Vaishampayan delivered an expansive overview of the current and future front-line therapies for patients with metastatic renal cell carcinoma (MRCC). According to most guidelines for MRCC, the first step in patient evaluation is to determine whether surgical resection is feasible or not.

ASCO GU 2017: A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). - Session Highlights

Orlando, Florida USA ( Dr. Powles presented a multi-institutional randomized phase II study evaluating the efficacy of first line therapies in metastatic renal cell carcinoma (mRCC). It is the first study of its kind comparing immune checkpoint + targeted therapy with antiangiogenic monontherapy.

ASCO GU 2017: Evolving Treatment Using Tyrosine Kinase Inhibitors and Immunotherapy in Metastatic Renal Cell Carcinoma - Session Highlights

Orlando, Florida USA ( Dr. Eric Jonasch stated it is well-known that tumor cells present antigens, which, in turn, are identified by CD8 T-cells, thus activating an immune response. Several receptors and ligands attenuate this immune response, such as CTLA4, programmed death-1, and programmed death-ligand-1.

ASCO GU 2017: Adjuvant Therapy of Renal Cell Carcinoma: Current Controversies - Session Highlights

Orlando, Florida USA ( In this session, Dr. Karam reported the current controversies in adjuvant management of renal cell carcinoma (RCC). The ideal adjuvant setting is a patient at high risk for recurrence, a drug active on microscopic cancer, low drug toxicity, inexpensive cost, and derivation of a clinically meaningful outcome.

ASCO GU 2017: Imaging as Biomarker of Response in Advanced Renal Cell Carcinoma - Session Highlights

Orlando, Florida USA ( Dr. Andrew D. Smith reported that a key challenge in the care of patients with metastatic renal cell carcinoma (RCC) is the assessment of tumor response following therapy. An ideal imaging biomarker would need to capture the therapy’s primary effect, have a simple objective metric, require being widely available and easy to perform on any scanner, seem applicable across a broad range of image-acquisition parameters, and be suitable for longitudinal tumor response assessment. Dr. Smith presented key imaging biomarkers to assess response in advanced RCC.
Page 1 of 3

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.